Cell-Free DNA Monitoring for Transplant Rejection Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods lack effective monitoring and assessment techniques for transplant complications, particularly for detecting donor-specific cell-free DNA (DS cf-DNA) and total cell-free DNA (cf-DNA) levels post-transplant, which are correlated with rejection grades, infections, and other complications, necessitating a reliable method for early detection and intervention.
Innovation Solution
The development of methods and compositions using multiplexed optimized mismatch amplification (MOMA) and sequencing techniques to quantify DS cf-DNA and total cf-DNA in transplant subjects, allowing for the determination of rejection grades, infections, and other complications, and guiding treatment and monitoring regimens.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional monitoring methods are used for transplant complications, then the monitoring process is simple, but the detection precision and ability to detect donor-specific cell-free DNA levels is insufficient
Solution Approach 1:
The monitoring method is segmented into distinct components: quantifying donor-specific cell-free DNA separately from total cell-free DNA, assessing rejection grades independently from infection detection, and evaluating transplant complications as distinct parameters. This segmentation enables precise measurement of each parameter while maintaining a systematic monitoring framework that manages complexity through structured analysis.
Solution Approach 2:
Cell-free DNA serves as an intermediary biomarker that mediates between the transplant graft status and the monitoring system. By measuring cf-DNA levels (both donor-specific and total) in the recipient's circulation, the method indirectly assesses graft rejection, infection, and other complications without requiring direct observation of graft tissue, thereby enabling non-invasive high-precision monitoring.
2Reliability
If early detection of transplant complications is implemented, then clinical outcomes are improved, but the complexity of monitoring techniques increases
Solution Approach 1:
The method performs preliminary assessment by quantifying cell-free DNA levels early in the post-transplant period to predict future complications before they manifest clinically. By measuring donor-specific cf-DNA and total cf-DNA at scheduled intervals, the system proactively identifies patients at risk for rejection, infection, or other complications, enabling early intervention that improves clinical outcomes while maintaining manageable monitoring complexity through standardized sampling protocols.
Solution Approach 2:
The monitoring system implements feedback loops where quantified cf-DNA levels are continuously compared against established thresholds and trends. When donor-specific or total cf-DNA levels exceed predetermined cutoffs or show concerning trajectories, the system triggers alerts for clinical review and potential intervention. This feedback mechanism transforms complex molecular data into actionable clinical decisions, improving reliability while keeping the monitoring process systematic and manageable.
3Loss of time
If frequent monitoring of cf-DNA levels is performed, then transplant complications are detected earlier, but the time and resources required for monitoring increase
Solution Approach 1:
The monitoring protocol employs periodic sampling at strategically determined intervals post-transplant, with frequency adjusted based on the patient's clinical status and risk factors. High-risk patients undergo more frequent cf-DNA quantification, while stable patients are monitored at extended intervals. This periodic approach enables early complication detection when clinically necessary while optimizing resource utilization by avoiding unnecessary frequent testing in low-risk scenarios, thereby balancing early detection benefits with monitoring efficiency.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
Enables early detection of transplant complications, facilitating timely intervention and improving clinical outcomes by accurately monitoring DS cf-DNA and total cf-DNA levels post-transplant, thereby reducing the risk of rejection and other adverse events.
Implementation Method 1
multiplexed optimized mismatch amplification (MOMA) and/or sequencing techniques
Data Source
AI summary
This invention relates to methods and compositions for monitoring an amount of donor-specific fraction and/or total cell-free DNA, such as from a transplant subject. The methods and composition provided herein can be used to assess a transplant subject to determine whether the subject has a “normal” or desirable decrease in cell-free DNA over the first few days following a transplant. Deviations from the “normal” course may be indicative of one or more transplant complications and/or a need for additional monitoring or treatment.